Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
78 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Liver Transplantation - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Liver Transplantation - Pipeline Review, H1 2016', provides an overview of the Liver Transplantation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Transplantation and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Liver Transplantation - The report reviews pipeline therapeutics for Liver Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Liver Transplantation therapeutics and enlists all their major and minor projects - The report assesses Liver Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Liver Transplantation Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Liver Transplantation - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Liver Transplantation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Liver Transplantation Overview 7 Therapeutics Development 8 Pipeline Products for Liver Transplantation - Overview 8 Pipeline Products for Liver Transplantation - Comparative Analysis 9 Liver Transplantation - Therapeutics under Development by Companies 10 Liver Transplantation - Therapeutics under Investigation by Universities/Institutes 11 Liver Transplantation - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Liver Transplantation - Products under Development by Companies 15 Liver Transplantation - Products under Investigation by Universities/Institutes 16 Liver Transplantation - Companies Involved in Therapeutics Development 17 Astellas Pharma Inc. 17 Conatus Pharmaceuticals Inc. 18 Digna Biotech, S.L. 19 Dompe Farmaceutici S.p.A. 20 Novartis AG 21 RedHill Biopharma Ltd. 22 Liver Transplantation - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 ABC-294640 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Cardiotrophin-1 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Cellular Immunotherapy for Liver Transplantation - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Cellular Immunotherapy for Liver Transplantation - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 emricasan - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 everolimus - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 FX-06 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 reparixin - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 tacrolimus ER - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 TR-002 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Liver Transplantation - Recent Pipeline Updates 55 Liver Transplantation - Dormant Projects 69 Liver Transplantation - Discontinued Products 70 Liver Transplantation - Product Development Milestones 71 Featured News & Press Releases 71 Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 71 May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients 71 Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 72 Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules 73 Oct 20, 2011: European Medicines Agency Agrees To Precautionary Recall Of Advagraf 0.5mg Capsule Batches 73 Jul 01, 2011: Astellas Introduces Advagraf In India 74 Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 74 Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant 74 Oct 02, 2007: New Once-Daily Advagraf Launched Across Europe. 75 Jun 18, 2007: Advagraf Now Available in Germany and the UK as a Once-Daily Immunosuppressant in Organ Transplantation 76 Appendix 77 Methodology 77 Coverage 77 Secondary Research 77 Primary Research 77 Expert Panel Validation 77 Contact Us 77 Disclaimer 78
List of Tables
Number of Products under Development for Liver Transplantation, H1 2016 8 Number of Products under Development for Liver Transplantation - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Liver Transplantation - Pipeline by Astellas Pharma Inc., H1 2016 17 Liver Transplantation - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 18 Liver Transplantation - Pipeline by Digna Biotech, S.L., H1 2016 19 Liver Transplantation - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 20 Liver Transplantation - Pipeline by Novartis AG, H1 2016 21 Liver Transplantation - Pipeline by RedHill Biopharma Ltd., H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Liver Transplantation Therapeutics - Recent Pipeline Updates, H1 2016 55 Liver Transplantation - Dormant Projects, H1 2016 69 Liver Transplantation - Discontinued Products, H1 2016 70
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
